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Reprogramming of fatty acid metabolism in cancer
Nikos Koundouros1 and George Poulogiannis1,2
A common feature of cancer cells is their ability to rewire their metabolism to sustain the production of ATP and macromolecules
needed for cell growth, division and survival. In particular, the importance of altered fatty acid metabolism in cancer has received
renewed interest as, aside their principal role as structural components of the membrane matrix, they are important secondary
messengers, and can also serve as fuel sources for energy production. In this review, we will examine the mechanisms through which
cancer cells rewire their fatty acid metabolism with a focus on four main areas of research. (1) The role of de novo synthesis and
exogenous uptake in the cellular pool of fatty acids. (2) The mechanisms through which molecular heterogeneity and oncogenic
signal transduction pathways, such as PI3K–AKT–mTOR signalling, regulate fatty acid metabolism. (3) The role of fatty acids as
essential mediators of cancer progression and metastasis, through remodelling of the tumour microenvironment. (4) Therapeutic
strategies and considerations for successfully targeting fatty acid metabolism in cancer. Further research focusing on the complex
interplay between oncogenic signalling and dysregulated fatty acid metabolism holds great promise to uncover novel metabolic
vulnerabilities and improve the efficacy of targeted therapies.
British Journal of Cancer (2020) 122:4–22; https://doi.org/10.1038/s41416-019-0650-z
BACKGROUND
Fatty acids (FAs) are the main building blocks of several lipid species,
including phospholipids, sphingolipids and triglycerides, and are
composed of a carboxylic acid group and a hydrocarbon chain
of varying carbon lengths and degrees of desaturation. They can
be funnelled into various metabolic pathways to synthesise more
complex lipid species, including diacylglycerides (DAGs) and
triacylglycerides (TAGs), or converted into phosphoglycerides, such
as phosphatidic acid (PA), phosphatidylethanolamine (PE) and
phosphatidylserine (PS).1 Consequently, FAs contribute to the vast
structural diversity of the cellular lipid pool, which in turn serves
to regulate several biochemical processes in normal cells. These
include synthesis of biological membranes and the modulation of
their fluidity, functioning as secondary messengers in signalling
pathways to maintain homoeostasis, and serving as a form of energy
storage in animals.2 More than 100 years of research have provided
tremendous insights into the integral role of FAs in tumorigenesis.
Examples include the increased reliance of cancer cells on de novo
biosynthesis and exogenous FA uptake to not only sustain their
rapid proliferative rate, but also provide an essential energy source
during conditions of metabolic stress (Fig. 1).3 In this review, we
will explore how cancer cells sustain their FA metabolism in the
context of a metabolically dynamic tumour microenvironment, and
oncogenic signalling to support tumorigenesis and cancer progres-
sion. By considering the interplay of the aforementioned processes,
we present opportunities to exploit metabolic dependencies as
viable therapeutic options to tackle cancer pathogenesis.
HOW DO CANCER CELLS OBTAIN FATTY ACIDS?
In mammalian cells, FAs can either be obtained through direct
exogenous uptake from the surrounding microenvironment or
synthesised de novo by using nutrients, such as glucose or
glutamine. It is widely accepted that a metabolic hallmark of
cancer cells is lipidomic remodelling, which broadly encompasses
alterations in FA transport, de novo lipogenesis, storage as lipid
droplets (LDs) and β-oxidation to generate ATP.4 However, the
specific mechanisms driving particular lipid phenotypes are
nuanced, and may be dependent on tumour type or molecular
sub-classifications.
Exogenous uptake of fatty acids allows for metabolic flexibility in
cancer cells
In terms of exogenous FA uptake, specialised transporters are
required to facilitate efficient movement across the plasma
membrane. The most well characterised of these include CD36,
also known as fatty acid translocase (FAT), fatty acid transport
protein family (FATPs), also known as solute carrier protein family
27 (SLC27) and plasma membrane fatty acid-binding proteins
(FABPpm), all of which display increased gene and protein
expression in tumours (Fig. 2).5 In particular, high CD36
expression has been correlated with poor prognosis across
several tumour types, including breast, ovarian, gastric and
prostate.6,7 In the case of highly aggressive Pten−/− prostate
cancers, CD36 promotes increased FA uptake and storage in LDs,
as well as significant alterations in lipid composition encom-
passing elevations in acyl-carnitines (ACs), monoacylglycerols
(MAGs) and other lysophospholipids, all of which are products of
FA oxidation (FAO).8 Notably, deletion of Cd36 is sufficient to
rescue the aforementioned phenotypes and mitigate tumour
growth, indicating that this FA transporter is integral for
promoting the lipidomic remodelling of Pten-deficient prostate
cancers.8 Collectively, these findings demonstrate that CD36
plays a key role in tumour microenvironment metabolic crosstalk,
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Fig. 1 Major discoveries in lipid research. Seminal studies demonstrating the importance of dysregulated fatty acid metabolism in cancer.
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Fig. 2 Cancer cells obtain fatty acids (FAs) from de novo lipogenesis and exogenous uptake. The exogenous uptake of FAs from the
surrounding microenvironment is facilitated by specialised transporters, including CD36, FATPs and FABPpm. FAs and their synthetic products
can be subsequently stored as LDs, and used for NADPH and acetyl-CoA production through β-oxidation. In terms of carbon sources for de
novo lipogenesis, cancer cells rely on glucose, glutamine and acetate to synthesise citrate. Palmitate is ultimately generated from citrate
through the enzymatic activities of ACLY, ACC and FASN, and can subsequently be desaturated and elongated to form a diverse group of lipid
species. An alternative pathway for palmitate desaturation exists, which generates sapienate through FADS2, instead of palmitoleate.
Abbreviations: GLUT1, glucose transporter 1; MCT, monocarboxylate transporter; CD36, cluster of differentiation 36; FATPs, fatty acid transport
proteins; FABPpm, fatty acid-binding protein; GLS, glutaminase; IDH1/2, isocitrate dehydrogenase; ACLY, ATP–citrate lyase; ACSS2, acyl-CoA
synthetase short-chain family member 2; ACC, acetyl-CoA carboxylase; FASN, fatty acid synthase; MUFAs, monounsaturated fatty acids; PUFAs,
polyunsaturated fatty acids; SCD, stearoyl-CoA desaturase-1; FADS2, fatty acid desaturase 2; ELOVLs, elongation of very long-chain fatty acid
protein; PA, phosphatidic acid; TAG, triacylglycerol; DAG, diacylglycerol; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PS;
phosphatidylserine.
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ultimately shifting the dependency of tumour cells towards
exogenous lipid uptake.
An intriguing observation during the metastatic dissemination
of breast, prostate and ovarian cancer cells is their preferential
homing to adipocyte tissue located in periglandular regions and
the visceral omentum.9 It has long been appreciated that adipose
tissue is implicated in metabolic syndromes such as obesity, and
functions as an endocrine system that secretes growth factors,
cytokines and free FAs following lipolysis.10 In this respect, co-
culture, as opposed to isolated, cell systems have been instru-
mental in our understanding of the impact of adipocytes on the
FA metabolism of cancer cells.11 Importantly, these seminal
studies have demonstrated that the migration and proliferation
of human ovarian cancer cells are significantly increased following
co-culture either directly with human-derived omentum adipo-
cytes, or their conditioned media.11 In these models, adipocytes
were shown to activate endogenous lipolysis of triglycerides to
produce free FAs that could be subsequently secreted and taken
up by metastatic cells overexpressing FABP4.11 The transfer of FAs
from surrounding adipocytes to metastatic ovarian cancer cells
also potentiated AMP-activated protein kinase (AMPK) signalling
in the latter, culminating in increased β-oxidation through
carnitine palmitoyltransferase 1 (CPT1) and acyl-CoA oxidase 1
activation.11 The overexpression of the FA translocase CD36 is also
essential for driving the progression of ovarian cancer, and
this is largely mediated through rapid exogenous uptake of long-
chain FAs and cholesterol that likewise, are obtained from the
adipocytes in the microenvironment.7
A major implication of elevated uptake of exogenous FAs is
their subsequent storage in LDs, which are cytoplasmic organelles
that sequester excess FAs in the form of TAGs and sterol esters.12
Consequently, the accumulation of LDs in cancer cells is used not
only to maintain lipid homoeostasis and prevent lipotoxicity, but
also to provide a valuable source of ATP and NADPH during
conditions of metabolic stress (Fig. 2).12,13 This is largely achieved
through β-oxidation of stored lipids, leading to the production of
acetyl-CoA through oxidative degradation of FAs.14,15 The acetyl-
CoA produced from each round of β-oxidation can subsequently
enter the tricarboxylic acid (TCA) cycle to generate NADH and
FADH2 for the electron transport chain, ultimately leading to the
synthesis of approximately six times more ATP than oxidation of
carbohydrates.14 Moreover, the oxidation of citrate derived from
acetyl-CoA by isocitrate dehydrogenase 1 (IDH1) is one of the
main sources of cellular NADPH production.16 Thus, β-oxidation of
LDs provides sufficient ATP to fuel the metastatic cascade, and
generates NADPH that is essential for anabolic metabolism and
detoxification of reactive oxygen species (ROS).17–20 This is
particularly relevant for hypoxic cells, which have elevated FA
uptake and accumulation of LDs following hypoxia-inducible
factor (HIF)-1α-dependent expression of FABP3 and FABP7.21 The
oxidation of triglycerides stored in LDs provides sufficient ATP to
facilitate the recovery of breast cancer and glioblastoma cells
during reoxygenation, whilst the increase in NADPH levels serves
to protect against ROS toxicity.21 Indeed, knockdown of FABP3
and FABP7 decreases the growth of U87 glioblastoma tumours
in vivo, an effect largely attributable to reduced FA uptake and
inhibition of LD formation.21
On a broader level, delineating the mechanisms driving
interactions between cancer cells and adipocytes has provided
fundamental insights into how obesity contributes to tumour
initiation and progression. This is particularly relevant for renal,
gastric, breast and colon cancers that preferentially grow in
adipocyte-rich environments.10 It is noteworthy that adipose
tissue associated with obesity recapitulates a state of persistent
inflammation characterised by the secretion of tumour necrosis
factor (TNF)-α, interleukin (IL)-6 and IL-8, as well as production of
vascular endothelial growth factor (VEGF), prostaglandins and
leukotrienes by activated macrophages.22 Thus, adipose cells can
function as active mediators of endocrine and paracrine signalling,
which in turn support the crosstalk between adiposity and cancer
cell FA metabolism.23 Indeed, this reciprocal crosstalk perpetuates
an interaction network in which secreted adipokines stimulate
cancer cells to release exosomes containing pro-lipolytic factors
such as miRNA-144 and miRNA-126, which in turn promote
lipolysis in adjacent adipocytes through activation of AMPK
signalling and induction of autophagy.9,24 Ultimately, enhanced
lipolysis and release of free FAs fundamentally alters the metabolic
dependencies of migrating cancer cells, shifting their reliance
towards exogenous lipid uptake and β-oxidation for energy
supply.24,25 These findings also point to a rationale for developing
therapies targeting the tumour microenvironment through
inhibition of adipocyte lipolysis, thereby reducing the availability
of free lipids for cancer cells.26
The uptake and scavenging of extracellular FAs also provides an
important compensatory mechanism for cancer cells to sustain
their lipid demands under conditions of metabolic stress. For
instance, the flux from glucose to acetyl-CoA decreases under
hypoxic conditions, and so does the conversion of saturated FAs
into monounsaturated FAs, as it is regulated by the oxygen-
consuming enzyme stearoyl-CoA desaturase-1 (SCD-1). Conse-
quently, hypoxic cells display increased uptake of exogenous
lysophospholipids, such as lysophosphatidylcholine (LPC), in order
to sustain their proliferation and survival.27 The regulation of
exogenous lipid uptake under hypoxia largely occurs through the
HIF-dependent overexpression of lipid-binding proteins. For
instance, FABP4 is a transcriptional target of HIF1α that facilitates
extracellular scavenging of long-chain unsaturated lysophospho-
lipids, including LPCs, lysophosphatidylethanolamines (LPEs) and
lysophosphatidylglycerols (LPGs) that can be used as a nutrient
source under conditions of metabolic stress.27,28 Interestingly, this
phenotype of increased FA scavenging is also recapitulated under
normoxic conditions following oncogenic Ras activation, and is
accompanied by reduced oxygen consumption, elevated citrate
synthesis from reductive carboxylation and a consequent inde-
pendence from SCD-1 to derive unsaturated FAs.27 Taken
together, these results demonstrate that whilst changes in the
microenvironment conditions or oncogenic activation of signal-
ling pathways confer resistance to SCD-1 inhibitors, they might
open novel opportunities for therapy by increasing the reliance of
cancer cells on FA uptake.
De novo lipogenesis allows for the synthesis of a diverse group of
fatty acids
De novo lipogenesis is the process through which carbon atoms
derived from carbohydrates such as glucose and amino acids
including glutamine are converted into FAs.29 In normal tissue, de
novo lipogenesis is restricted to hepatocytes and adipocytes;
however, cancer cells may also reactivate this anabolic pathway
even in the presence of exogenous lipid sources.3,30 The main
substrate for FA synthesis is cytoplasmic acetyl-CoA that can either
be derived from citrate or acetate.3 Carbons from glucose or
glutamine contribute to citrate production either from the
oxidation of pyruvate in the TCA cycle or through reductive
carboxylation, respectively.31,32 In addition, under conditions of
metabolic stress such as hypoxia or lipid depletion, cancer cells
upregulate acetyl-CoA synthetase 2 (ACSS2) in order to generate
acetyl-CoA from acetate.33 Citrate is converted into acetyl-CoA
by ATP–citrate lyase (ACLY), which is the substrate for the
carboxylating enzymes acetyl-CoA carboxylases (ACCs).26,34 The
irreversible carboxylation of acetyl-CoA into malonyl-CoA is the
rate-limiting step of de novo lipogenesis, and it is the condensa-
tion of seven malonyl-CoA molecules and one molecule of acetyl-
CoA catalysed by fatty acid synthase (FASN), which ultimately
produces the saturated 16-carbon FA palmitate (FA16:0).26,35
Subsequent desaturation of palmitate by stearoyl-CoA desaturase
(SCD) produces monounsaturated FAs with a double bond at
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position Δ9, whilst elongation by FA elongases, such as ELOVL6,
adds two-carbon groups to palmitate in order to form the
saturated FA stearate (Fig. 2).26,36,37
The regulation of de novo lipogenesis occurs largely at the
transcriptional level through the activation of sterol regulatory
element-binding proteins (SREBPs), of which three main transcrip-
tion factors exist: SREBP1a and SREBP1c arising from the
alternative splicing of SREBPF1, and SREBP2 encoded by the
SREBPF2 gene.38 SREBPs are initially found as inactive 125-kDa
precursors, bound to the endoplasmic reticulum (ER). At saturated
concentrations of intracellular cholesterol, insulin-induced genes
(INSIGs) bind to SREBP-cleavage-activating proteins (SCAPs) and
localise the SREBP precursors to the ER.39,40 Conversely, under
conditions of low cholesterol levels, SCAPs facilitate the transloca-
tion of ER-bound SREBPs to the Golgi, where the transcription
factor is subsequently cleaved by membrane-bound transcription
factor site 1 proteases (MBTPS1 and MBPTS2) to release the active
N terminus.41,42 Ultimately, it is the N-terminal fragment that
translocates to the nucleus and induces the transcription of genes
containing sterol regulatory elements (SREs), such as FASN, ACLY
and ACC.26,43,44
One of the main advantages for cancer cells to sustain higher de
novo lipogenesis of FAs is their flexibility to shunt them into
different biosynthetic pathways to generate a diverse cellular pool
of lipid species with distinct functions. Indeed, upregulation of
lipid synthesis, followed by downstream elongation and desatura-
tion pathways, has been shown to be sufficient to produce all FAs
from the nutrients, such as glucose, glutamine and acetate, which
are required for adipocyte differentiation.45 Palmitate (FA16:0) is
the main product of de novo lipogenesis, and can be elongated
and desaturated through the activity of SCD, ELOVLs and FADs to
produce additional FA species including stearate (FA18:0) and
oleate (FA18:1) (Fig. 2).46 These FAs can be subsequently used for
the production of more complex lipids. Notably, oleate can
directly feed into PA synthesis through the enzymatic activities of
glycerol-3-phosphate acyltransferase 1 (GPAT1) and acyl-CoA:LPA
acyltransferase (LPAT), as well as being incorporated into TAGs for
storage in a GPAT1-dependent fashion.47–49 With respect to PA,
this class of phospholipid not only serves important structural and
signalling roles, but is also one of the main substrates for DAG
synthesis by Lipin1–3 and AGPAT, as well as contributing to the
biosynthesis of complex glycerolipids.50,51 For instance, PA can be
condensed with CTP through a reaction catalysed by CDP–DAG
synthase (CDS) to generate CDP–DAG.52,53 Importantly, CDP–DAG
is the main precursor for the de novo synthesis of complex
glycerolipids including phosphatidylinositols (PtdIns), phosphati-
dylserines (PSs), phosphatidylglycerols (PGs) and phosphatidyl-
cholines (PCs) (Fig. 2).54
More recently, studies have begun to elucidate the various
compensatory pathways implicated in FA metabolism that cancer
cells exploit to increase their adaptability. This has been most
extensively studied with the SCD enzymes, which were previously
thought to be the only desaturases that generate monounsatu-
rated FAs from palmitate. SCDs are necessary for tumorigenesis as
they regulate the cellular pool of unsaturated FAs that later serve
as building blocks for phosphoglycerides, phosphoinositides,
eicosanoids and sphingolipids. As a result, they constitute an
attractive target for therapeutic intervention; however, inhibitors
targeting these metabolic enzymes have only shown modest
effects.55,56 This suggests that cancer cells may rely on alternative
desaturation pathways to generate functionally useful lipid
species, thus relieving their dependence on canonical SCD-
mediated desaturation. Indeed, FADS2 has been shown to play
a dominant role in FA desaturation in cancer cell lines and primary
tumours that are resistant to SCD inhibitors.57 Of note, these cells
exploit an alternative pathway involving the FADS2-dependent
desaturation of palmitate to sapienate (cis-6-C16:1) to support
their membrane synthesis during proliferation.57
THE CONTEXT-DEPENDENT REGULATION OF LIPID
METABOLISM: CONVERGENCE OF MOLECULAR
HETEROGENEITY AND ONCOGENIC SIGNALLING
Several metabolic processes in cancer cells are directly regulated
by oncogenes and tumour suppressors. For instance, mutant KRAS
enhances glycolysis in pancreatic cancer cells through upregula-
tion of the genes encoding hexokinase 1/2 (Hk1 and Hk2,
respectively), and redirects glutamine flux to malate for the
production of pyruvate and reducing power in the form of
NADPH.58,59 Moreover, amplification of the MYC oncogene drives
increased glutamine metabolism and anaplerosis by transcription-
ally activating mitochondrial glutaminase (GLS1) and the SLC1A5
glutamine transporter.60,61 Hyperactivation of the phosphoinosi-
tide 3-kinase and AKT (PI3K–AKT) pathway has also been
implicated in the rewiring of specific metabolic processes,
including increased glucose uptake through stabilisation of
glucose transporter 1 (GLUT1), enhanced glutamine anaplerosis
via activation of glutamate pyruvate transaminase 2 (GPT2) and
remodelling of the cellular lipidome.62–64 It is also becoming
increasingly appreciated that the complex regulatory networks
involved in FA metabolism must be considered in specific
molecular and metabolic contexts. These include the impact of
molecular heterogeneity, as exemplified by the intrinsic subtypes
of breast cancer, as well as the oncogenic processes that drive
malignant transformation in different cancers.
Molecular heterogeneity and lipid reprogramming
Gene expression analyses have long suggested that upregulation
of several enzymes involved in lipid metabolism is a near-universal
metabolic hallmark of cancer cells.4,65 However, more nuanced
observations from these genomic studies highlight differences in
the expression of lipid enzymes across different tumour types and
molecular sub-classifications.4 For instance, long-chain acyl-CoA
synthetase 3 (ACSL3) is overexpressed in androgen-dependent
cancers, such as prostate tumours, where it activates cholesterol
synthesis and steroidogenesis, but it is downregulated in triple-
negative breast cancers.66,67 Furthermore, enzymes involved in
β-oxidation such as α-methylacyl-CoA racemase (AMACR) and
CPT1B are specifically overexpressed in colorectal, hepatic and
prostate cancers, whilst CPT1A is upregulated in breast cancer.4,68
The upregulation of AMACR in prostate cancer is highly significant
to the extent that it is used as a bona fide biomarker for early
detection and diagnosis of prostate cancer.68 Furthermore, it also
suggests that β-oxidation, particularly of branched-chain FAs, is
the main bioenergetic pathway for obtaining ATP and NADPH in
prostate cancer cells.69 Clinically, prostate cancers display low
rates of glycolysis, and are therefore poor candidates for
diagnostic imaging by using fludeoxyglucose positron emission
tomography (FDG-PET).70 The higher dependence on FAO could
serve as an alternative metabolic signature for prostate cancer
diagnosis, and indeed this dependency is currently being explored
as a novel imaging application through the use of C11-acetate PET
tracers.70 Thus, although dysregulated lipid metabolism is a broad
feature of cancer, different tumour types may exhibit unique
metabolic adaptations that contribute to the remodelling of their
lipidome.
The regulatory complexity of lipid metabolism in the context of
molecular heterogeneity is perhaps best exemplified in breast
cancer, which comprises multiple different subtypes characterised
by unique hormone/growth-factor receptor expression and
genetic profiles.71 Comparative mRNA expression analyses
between receptor-positive and triple-negative breast cancers
(RPBC and TNBC, respectively) have revealed notable differences
between these subtypes in terms of lipid procurement, storage
and oxidation.4 Interestingly, RPBCs are associated with a gene
signature encompassing elevated de novo lipogenesis, FA
mobilisation and oxidation, whilst TNBCs overexpress genes
involved in exogenous lipid uptake – including FABP5 and
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FABP7 – and storage.4 It is also notable that TNBCs are dependent
on different ACSL isoforms when compared with RPBCs to
mobilise FAs that have been stored in LDs.4 Specifically, over-
expression of ACSL4 in TNBCs is associated with the enhanced
metabolism of arachidonic acid to arachidonyl-CoA that can be
used as a substrate for cyclo-oxygenase 2 (COX2) for prostaglan-
din synthesis.4 The co-ordinated synthesis of pro-inflammatory
prostaglandins from LDs may, in turn, contribute to the more
aggressive phenotypes generally observed in TNBCs compared
with RPBCs.4,72
Although gene expression analyses may not necessarily
provide a direct reflection of enzyme activity or dependencies
on specific metabolic pathways, studies have validated unique
lipid-associated genetic signatures that can be used to guide
therapeutic intervention.67,73 For instance, a subset of TNBCs with
MYC overexpression have been shown to upregulate several
genes involved in β-oxidation, such as PGC1α, CPT1B and CDCP1,
whilst downregulating FASN and ACACB.73 Importantly, a genetic
signature associated with FAO contributes to the aggressiveness
and poor clinical outcome of MYC-high TNBCs, suggesting that it
is an essential bioenergetics pathway of these tumours.73 Indeed,
inhibition of CPT1 and consequently FAO with etomoxir sig-
nificantly reduces the primary tumour growth of MYC-high, but
not MYC-low, TNBCs or RPBCs.73 The potential to exploit the
metabolic dependency of TNBCs on β-oxidation has also been
demonstrated for the treatment of metastatic disease, with the
inhibition of CUB-domain-containing protein 1 (CDCP1) signifi-
cantly impairing the capacity of TNBCs to oxidise FAs stored in LDs
during migration and metastasis.67 Overall, rather than consider-
ing dysregulated lipid homoeostasis as a general feature of cancer
cells, it is important to understand the molecular subtype, tissue
and the overall tumour microenvironment context of such
changes. This will undoubtedly lead to better stratification
methods and targeted application of metabolic inhibitors that
block specific pathways involved in lipid metabolism.
Regulation of lipid metabolism by oncogenic signalling
Oncogenic signalling pathways can directly regulate metabolic
enzymes involved in lipid metabolism, and are therefore integral
in shaping the tumour lipidome. The most frequently dysregu-
lated signalling pathway in human cancers is PI3K–AKT signalling,
which can be activated through the stimulation of growth-factor
receptor tyrosine kinases (RTKs) including human epidermal
growth-factor receptor 2 (HER2) and the insulin receptor, or
acquirement of oncogenic mutations in PIK3CA, the gene
encoding the p110α catalytic subunit of class I PI3Ks.74–77 PIK3CA
is, in fact, one of the most commonly mutated genes in
carcinomas, with up to a third of all human cancers and 40% of
breast cancers carrying gain-of-function mutations.78 There have
been several extensive reviews on the specific nodes that
constitute PI3K signalling,74,75,79 and their oncogenic conse-
quences in terms of promoting growth, proliferation and survival,
hence these concepts are only briefly introduced here.
HER2-amplified breast cancers are closely associated with
hyperactivation of PI3K signalling, with more than 80% of tumours
displaying increased phosphorylation of AKT on Ser473 and
Thr308.80 Furthermore, an important feature of HER2-positive
tumours that contributes to their aggressiveness is sustained
upregulation of de novo lipogenesis.81 Indeed, overexpression of
HER2 in non-transformed epithelial cells induces a lipogenic
phenotype dependent on FASN activation that is reminiscent of
cancer cells, whilst inhibition of HER2 or de novo lipogenesis
ablates oncogenic activity and induces apoptosis.82 This suggests
that oncogenic signalling downstream of HER2 may activate
several complementary pathways that converge on increased
lipogenesis. Activation of AKT contributes to two essential
processes for de novo lipid synthesis: the shuttling of metabolic
intermediates to provide carbon sources for anabolism, and the
synthesis of reducing equivalents in the form of NADPH to fuel
lipogenesis.83 For instance, AKT can directly phosphorylate and
activate ACLY, thus increasing acetyl-CoA synthesis.84 Moreover,
NADPH is an essential cofactor for anabolic metabolism, and
specifically for the condensation reaction of acetyl-CoA and
malonyl-CoA catalysed by FASN.85 AKT can indirectly promote
NADPH production by activating the nuclear factor-like 2 (Nrf2)
transcription factor,20,86 leading to the transcription of genes
involved in NADPH synthesis, including 6-phosphogluconate
dehydrogenase (6PGD), glucose-6-phosphate dehydrogenase
(G6PD) and malic enzyme 1 (ME1).87,88 More recently, AKT has
been shown to directly contribute to the cellular pool of NADPH
by acutely activating nicotinamide adenine dinucleotide kinase
(NADK), resulting in increased nicotinamide adenine dinucleotide
phosphate (NADP+) production.89 Mechanistically, AKT-mediated
phosphorylation of NADK at Ser44, Ser46 and Ser48 within the N-
terminal domain maintains NADK in an active state by preventing
its autoinhibition.89 Importantly, NADK is the only enzyme in
mammalian cells that converts NAD+ into NADP+, the latter
of which can be reduced to NADPH to sustain de novo lipogenesis
(Fig. 3).89
Intimately linked with PI3K activation is signalling through the
mammalian target of rapamycin (mTOR) complexes. mTOR is a
serine/threonine protein kinase that is the predominant catalytic
subunit of the protein complex mTOR complex 1 (mTORC1) and
mTOR complex 2 (mTORC2).90 Both are multiprotein complexes,
and are distinguished mainly through their associations of either
Raptor (regulatory protein associated with mTOR) in mTORC1, or
Rictor (rapamycin-insensitive companion of mTOR) in mTORC2.90
AKT is a potent activator of mTORC1 by phosphorylating and
inactivating its main negative regulators tuberous sclerosis
complex components 1 and 2 (TSC1/2).90 Several metabolic
processes are activated by mTORC1, including oxidative phosphor-
ylation by promoting mitochondrial biosynthesis,91 sustaining de
novo nucleotide synthesis92 and lipogenesis.93 The processing of
the lipogenesis transcriptional regulator SREBP1 into its mature
active form is strongly influenced by PI3K–AKT–mTORC1-depen-
dent mechanisms; hence, the expression of key lipogenic enzymes,
such as FASN, ACC1 and ACLY is suppressed following mTORC1
inhibition by acute rapamycin inhibition or Raptor knockdown.93,94
One of these mechanisms involves the mTORC1-dependent
regulation of lipin-1.95 Interestingly, mTORC1 directly phosphor-
ylates and inactivates lipin-1 leading to its sequestration in the
cytoplasm.95 Upon mTORC1 inhibition, active lipin-1 translocates to
the nucleus and induces significant nuclear reshaping, culminating
in reduced SREBP-transcriptional activity (Fig. 3).95 Although not
fully elucidated, this regulation may be dependent on the lipid
phosphatase activity of lipin-1 that specifically acts on PAs: it is,
therefore, conceivable that modulation of the lipid architecture in
the nucleus and subsequent alteration of the nuclear lamina may
directly affect SREBP activity.95 mTORC1 also regulates the
expression of lipogenic genes independently of SREBPs.96 Mechan-
istically, this requires the mTORC1–S6 kinase 1 (S6K1)–serine/
arginine protein kinase 2 (SRPK2) activation of the U1 small nuclear
ribonucleoprotein 70 kDa (U1-70K), leading to increased mRNA
splicing of genes involved in de novo lipogenesis such as FASN,
ACLY and ACSS2 (Fig. 3).96 Notably, inhibition of mTORC1 with
Torin-1 reduces spliceosome formation, and knockdown of
SRPK2 significantly attenuates mRNA stability and expression of
the aforementioned lipogenic enzymes, resulting in reduced
tumour growth in vivo.96
It is noteworthy that several oncogenes converge on mTORC1 to
promote lipogenesis. One of the most relevant in the context of
tumorigenesis is activation of Ras.97 KRAS in particular is frequently
mutated in colorectal and non-small-cell lung carcinomas, with the
G12V missense accounting for the majority of detected mutations.97
Consequent activation of extracellular signal-regulated kinase 1/2
(ERK1/2) activates mTORC1 through inhibition of TSC1/2, and
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contributes to lipidomic rewiring encompassing elevated synthesis
of glycerophospholipids and FAs including palmitate, oleic acid and
docosahexaenoic acid in lung cancers.94,98,99 Furthermore, KRASG12V
also contributes to increased incorporation of acetate into
endogenously synthesised lipids, potentially suggesting a depen-
dence on ACSS2 to synthesise acetyl-CoA for de novo lipogenesis.94
In addition to mTORC1, hyperactivation of PI3K signalling can
also induce mTORC2 activity, and although less well characterised
than mTORC1, it is becoming increasingly appreciated that
mTORC2 is an important mediator of metabolic reprogramming
in cancer cells. mTORC2 functions as a pivotal signalling hub for
driving FA metabolism, and this is mediated not only through the
activation of downstream AGC kinases, including AKT, serum- and
glucocorticoid-regulated kinases (SGKs) and protein kinase Cs
(PKCs), but also through reciprocal stimulation of mTORC2 by AKT
following phosphorylation of SIN1 on Thr86.79,100,101 In support of
a broad role of mTORC2 at regulating whole-body metabolism,
Rictor knockout causes insulin insensitivity characterised by
reduced glucose uptake in hepatocytes and overall attenuation
of insulin-stimulated de novo lipogenesis through inhibition of
SREBP1c maturation.100 An important role for mTORC2 signalling
in tumorigenesis has been established in hepatocellular carcino-
genesis, where it drives the progression of fatty liver disease to
cancer in liver-specific PTEN−/− and Tsc1−/− mouse models.102
Through activation of SREBP1c, mTORC2 induces widespread
alterations in the hepatocellular lipidome culminating in de novo
synthesis of sphingolipids, glycerophospholipids and cardiolipins,
which increase mitochondrial respiration.102 Importantly, inhibi-
tion of mTORC2, but not mTORC1, leads to a reduction in the
elevated expression of de novo lipogenesis genes including FASN,
and overall hepatocellular lipid content, culminating in attenuated
growth of PTEN- and Tsc1-null hepatocellular carcinomas.102 These
observations are particularly relevant in light of previous in vivo
data suggesting that mTORC1 activation alone is insufficient to
stimulate lipid synthesis without functional AKT.103
Independently of mTORC1, AKT promotes the stability of
mature SREBP1c by inhibiting glycogen synthase kinase-3
(GSK3), which phosphorylates and promotes its ubiquitylation
and proteasomal degradation (Fig. 3).104 In addition, by
inhibiting the expression of Insig2, AKT positively regulates the
translocation of SREBP1c from the ER membrane to the Golgi
apparatus, where it can be processed into the transcriptionally
active form.103 Therefore, it is conceivable that mTORC2
activation and its downstream signalling nodes could play a



























































Fig. 3 Regulation of lipid metabolism by PI3K–mTOR signalling. PI3K signalling is the most frequently dysregulated pathway in cancer, and
stimulates growth, proliferation and survival. Activation of receptor tyrosine kinases recruits PI3Kα to the plasma membrane where it
phosphorylates PIP2 to PIP3. AKT binds to PIP3, allowing activation by PDK1 and mTORC2. AKT directly promotes lipogenesis by stabilising
SREBP1c through inhibition of GSK3β, activation of ACLY to generate acetyl-CoA and phosphorylation of NADK to produce NADP+ for NADPH
synthesis. PI3K signalling is also closely linked to mTORC1 and mTORC2. mTORC1 regulates lipogenesis through inhibition of lipin-1, which is a
negative regulator of nuclear SREBP1c, and activation of the splicing factor SRPK2, thereby promoting the expression of lipogenic enzymes,
including ACLY, FASN and ACSS2. Finally, mTORC2 activation supports lipogenesis through AKT-dependent and -independent mechanisms,
with the latter encompassing phosphorylation of SGK1 and PKCs, and subsequent activation of SREBP1c. Abbreviations: PIP3,
phosphatidylinositol (3,4,5)-trisphosphate; PIP2, phosphatidylinositol (4,5)-bisphosphate; mTORC, mammalian target of rapamycin complex;
SREBP, sterol regulatory element-binding protein; SGK, serum- and glucocorticoid-induced protein kinase 1; PKC, protein kinase C; GSK3,
glycogen synthase kinase; FBXW7, F-Box and WD repeat domain containing 7; ACLY, ATP–citrate lyase, PDK1, phosphoinositide-dependent
kinase 1; NADK, NAD+ kinase; NAD+, nicotinamide adenine dinucleotide; NADP+, nicotinamide adenine dinucleotide phosphate; SRPK2; SR-
protein-specific kinase 2; S6K1, ribosomal protein S6 kinase β-1; FASN, fatty acid synthase; ACC, acyl-CoA synthetase short-chain family
member 2.
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An important aspect of mTORC2 signalling is its capacity to
stimulate several AKT-independent compensatory signalling axes,
posing significant challenges for the successful therapeutic
targeting of PI3K–mTOR signalling.105 In addition to AKT, mTORC2
can directly phosphorylate and activate several SGK and PKC
isoforms that can stimulate lipogenesis (Fig. 3). For instance, in
yeast models, mTORC2 promotes ceramide synthesis by activating
Ypk2, the human orthologue of which is SGK1.106 Although not
yet comprehensively studied in human cells, the potential
regulation of ceramide synthesis by mTORC2 and SGK1 could
provide a compensatory pathway for sustaining glyceropho-
spholipid synthesis in cancer independently of canonical
AKT–mTORC1 activities.106 In terms of PKC signalling, mTORC2
phosphorylates the hydrophobic motif of several isoforms,
including PKCβII, PKCε and PKCζ on Ser660, Ser729 and Thr560,
respectively (Fig. 3).107–109 The regulation of cancer cell metabo-
lism by PKCs has been characterised in the context of lipid
homoeostasis and includes the PKCβ-dependent stimulation of de
novo lipogenesis by activating the transcription of SREBPF1
directly through recruitment of Sp1 to the promoter region.110
Moreover, the atypical PKCζ and PKCλ/ι isoforms have been
shown to be the predominant mediators of hepatic lipogenesis
downstream of insulin-induced PI3K signalling.111 The expression
of SREBPF1, FASN, as well as glucose uptake, cholesterol and
triglyceride levels, are all reduced following deletion of Pik3r1
and Pik3r2.111 Notably, reconstituting myristoylated AKT restores
hepatic glucose metabolism, whilst SREBP1c expression and
lipogenesis are rescued following overexpression of PKCζ/λ.111
These findings indicate that PI3K signalling regulates metabolic
homoeostasis in the liver through two distinct pathways: one
involving AKT-dependent glucose uptake, and the second
requiring PKCζ/λ to sustain lipid synthesis.111
It is well established that PI3K signalling regulates a myriad of
cellular metabolic processes in cancer, but how these are integrated
in the context of dysregulated FA metabolism is still obscure. The
PI3K–AKT pathway is well-known to be the major signalling cascade
contributing to the Warburg effect by directly facilitating glucose
uptake and glycolysis through activation of GLUT1 and hexoki-
nase.112 Furthermore, AKT has been shown to promote HIF1α
mRNA translation in an mTORC1-dependent fashion even under
aerobic conditions, thus contributing to uncoupling of glycolysis
and mitochondrial oxidative phosphorylation through inhibition of
pyruvate dehydrogenase.113 If one is to consider this metabolic
rewiring in isolation, then it becomes counterintuitive as to how
PI3K signalling promotes lipid metabolism, particularly when
functional oxidative phosphorylation is required for citrate synthesis
during lipogenesis and β-oxidation.
It is, therefore, necessary to re-examine the notion that cancer
cells displaying elevated aerobic glycolysis must also have
impaired oxidative phosphorylation. In the context of PI3K
signalling, metabolic pathways contributing to both the synthesis
of metabolic intermediates required for lipogenesis and promo-
tion of mitochondrial bioenergetics are activated. For instance,
glucose-6-phosphate generated during the first step of glycolysis
can be shunted to the pentose phosphate pathway (PPP) to
contribute in the production of NADPH, which plays a key role in
the sustainment of anabolic processes and detoxification of ROS in
rapidly proliferating cells.88,114 As discussed previously, AKT can
also directly facilitate NADPH synthesis following phosphorylation
and activation of NADK.89 Furthermore, mTORC1 and mTORC2
downstream of oncogenic PI3K promote oxidative phosphoryla-
tion through PGC-1α-dependent mitochondrial biosynthesis, and
synthesis of cardiolipins, which enhance respiration and improve
mitochondrial activity.91,102 Therefore, hyperactive PI3K signalling
provides a clear metabolic advantage to cancer cells as it not only
increases the synthesis of metabolic intermediates required for
anabolic metabolism, but also promotes respiration to generate
citrate from acetyl-CoA for de novo lipogenesis.
In general, PI3K–AKT signalling promotes lipid synthesis whilst
inhibiting lipolysis and β-oxidation.115 However, the precise
involvement of the PI3K pathway in balancing the oxidation of
FAs and glucose is more complex. Insights have been provided by
studies focussing on glucose and lipid homoeostasis in type 2
diabetes. Hyperinsulinaemia activates the insulin receptor and
PI3K signalling, contributing to increased CD36 membrane
translocation and uptake of exogenous FAs.116 At the onset of
insulin resistance, GLUT4 expression and translocation is inhibited,
leading to increased blood glucose levels, decreased glycolysis
and high FA β-oxidation of intracellular lipid pools.117 In terms of
specific mechanisms, the accumulation of FAs in response to
insulin resistance may drive DAG synthesis, which can activate
conventional PKC isoforms, leading to the phosphorylation of
insulin receptor substrate 1 (IRS1) and consequent inhibition of
PI3K–AKT signalling.118 Moreover, dysregulated lipid signalling
could induce a negative-feedback loop initiated by the activation
of mTORC1–p70S6K and its subsequent phosphorylation-induced
inhibition of IRS1.119,120 Given that insulin resistance and obesity
are becoming increasingly associated with cancer, it is conceivable
that PI3K signalling is central to this phenomenon. In this context,
attenuation of PI3K signalling following obesity-induced insulin
resistance may shift the metabolic balance from lipid synthesis to
lipolysis and β-oxidation.115 As previously discussed in this review,
increased lipolysis particularly in adipocyte-rich microenviron-
ments generates free FAs that can be utilised by cancer cells,7,11
whilst β-oxidation contributes to ATP and NADPH synthesis.14
Thus, the effects of PI3K signalling on lipid metabolism and
tumorigenesis are paradoxical: on one hand, active PI3K signalling
supports tumorigenesis through enhanced de novo lipogenesis,
but on the other it inhibits lipolysis and β-oxidation, both of which
are key at promoting cancer cell proliferation and metastasis. In
order to reconcile the seemingly disparate regulatory mechanisms
linking PI3K signalling and lipid metabolism, it may be necessary
to consider whole-body metabolism and obesity as factors that
dictate the dependencies of tumours for specific metabolic
pathways.
Regulation of oncogenic signalling by fatty acid metabolism
Thus far, rewiring of the tumour lipidome has been largely
discussed as a consequence of hyperactive oncogenic signalling
and genetic aberrations. However, it is also important to
acknowledge that overexpression of several lipogenic enzymes
occurs relatively early in tumorigenesis, and can be observed in
both hyperplastic and preinvasive lesions.65,121 Therefore, it is
conceivable that upregulation of de novo lipogenesis and the
enzymatic network that regulates it may also dynamically and
reciprocally potentiate oncogenic signalling throughout malignant
transformation, rather than representing a secondary phenom-
enon. In support of this, mechanisms linking the bidirectional
crosstalk between FASN and oestrogen receptor α (ERα) signalling
have been elucidated in hormone-dependent breast cancers. In
these models, both genetic and pharmacological inhibition of
FASN hypersensitises ERα to oestrogen-dependent transactivation,
thus leading to a synergistic induction of both oestrogen receptor
element (ERE) transcriptional activity and mitogen-activated
protein kinase (MAPK)–ERK signalling.122 Surprisingly, oestrogen
stimulation following FASN inhibition has significant cytotoxic and
cytostatic effects, despite activation of the seemingly pro-
tumorigenic aforementioned processes.122 Whilst this may seem
paradoxical at first, these findings highlight a novel role for FASN
in modulating the thresholds required for triggering hormone
receptor signalling, and consequently regulating the balance
between the opposing pro-tumorigenic and anti-proliferative
effects of ERα stimulation. For instance, although oestrogen
signalling contributes to the upregulation of genes involved in
proliferation, invasion and metastasis – such as Twist and matrix
metalloproteinases 2/9 (MMP2/9) – FASN blockade leads to the
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nuclear accumulation of the oestradiol (E2) targets p21
WAF/CIP1 and
p27Kip1, culminating in cell-cycle inhibition and induction of
cytostatic and cytotoxic effects in response to E2 exposure.
122,123
Moreover, it is interesting to note that while E2 hyperactivates
MAPK–ERK signalling following FASN inhibition, PI3K–AKT activity
is attenuated.122 Indeed, there exists significant crosstalk between
MAPK–ERK and PI3K–AKT signalling encompassing both positive-
and negative-feedback loops, and this may explain at least one of
the mechanisms responsible for the observed effects of FASN
blockade and E2 exposure.
124 In terms of cross-inhibition, ERK has
been shown to phosphorylate the scaffold protein GRB2-
associated-binding protein 1 (GAB1), thus compromising the
recruitment of PI3K to the plasma membrane and downstream
activation of AKT.125 Therefore, in addition to its role in de novo
lipogenesis, FASN is also at the nexus of pathway integration
between MAPK–ERK and PI3K–AKT pathways, and their interaction
with E2–ERα signalling.
122
Molecular connections have also been made between FASN
and HER2 overexpression.121 These have largely been described at
the transcriptional level, with inhibition of FASN leading to
upregulation of the ets-DNA-binding protein PEA3 – a negative
regulator of HER2 gene transcription – and consequent reduction
in HER2 mRNA expression.82,126 An additional layer of regulation
involves the cellular localisation of HER2 in response to FASN
levels and activity. Notably, small-interfering RNA (siRNA)-
mediated silencing of FASN expression or chemical inhibition by
using C75 markedly attenuates the membrane accumulation of
HER2 and is also associated with broader alterations in cell
morphology.82 Given that FASN is predominantly involved in the
synthesis of saturated FAs, and these, in turn, modulate cell
membrane dynamics including fluidity and lipid raft formation,
inhibiting this lipogenic enzyme not only impairs the appropriate
localisation of HER2 to the plasma membrane, but also impinges
on the dimerisation of HER2 with epidermal growth-factor
receptor (EGFR) that drives resistance to lapatinib and
trastuzumab.82,127 Indeed, dual treatment with cerulenin and
trastuzumab synergistically increases apoptosis in HER2-amplified
breast cancer cells, indicating that FASN inhibition, and its
associated effects on HER2 expression and localisation, could be
an attractive combinatorial therapeutic target in this breast cancer
subtype.82 Furthermore, as HER2-amplified tumours are particu-
larly dependent on PI3K signalling, FASN could play a central role
in modulating the initiation of growth-factor-dependent onco-
genic signalling that is required for malignancy.128–132
Metabolic regulation of the cancer epigenome
In addition to the modulation of pro-tumorigenic signalling
networks, there is accumulating experimental evidence that FA
metabolism exerts profound effects on the cancer epigenome,
and this, in turn, regulates gene expression and cellular
differentiation.133 A central role for ACLY and ACSS2 has been
defined in this context as these enzymes are the major sources of
acetyl-CoA, which is an essential cofactor for several histone-
modifying enzymes.134,135 Activation of ACLY following phosphor-
ylation on Ser455 by AKT directly promotes acetyl-CoA synthesis
and increases global histone acetylation levels, even when
nutrient availability is limiting.136 Under metabolically stressful
conditions such as hypoxia, ACSS2 is also involved in the nuclear
recycling of acetate to acetyl-CoA, and this, in turn, promotes
acetylation of histones to increase the transcription of lysosomal
and autophagy-related genes, which are essential for maintaining
energy homoeostasis in cancer cells.137 Importantly, the sustained
synthesis of acetyl-CoA by ACLY and ACSS2 maintains a histone
acetylation profile that promotes the transcription of pro-
proliferative and growth genes even under nutrient-deplete
conditions, thus allowing cancer cells to more rapidly induce
these tumorigenic genetic programmes when microenvironmen-
tal conditions become favourable.134
The availability of acetyl-CoA also regulates cell differentiation
and stemness. This is particularly relevant in cancer, as the
presence of a stem-cell niche is thought to contribute to the
limitless replicative potential of a tumour, as well as restoring
growth of lesions that arise from therapy relapse.138 In haemato-
logical malignancies, for instance, acetyl-CoA is an obligate
cofactor for CREB-binding protein (CBP)/p300, which activates
the transcription factor c-Myb and induces the expression of the
self-renewal genes Oct4, Sox2, Klf4 and CSF1R.139 The regulation of
acetyl-CoA metabolic pathways also contributes to disease
progression in pancreatic ductal adenocarcinoma (PDA), with
oncogenic KRAS mutations co-operating with ACLY and ACSS2
activity to promote proliferation and metastasis.140 Acetyl-CoA-
induced epigenetic remodelling in PDA creates a histone profile
reminiscent of the foregut endoderm in the developing embryo,
and is characterised by a transcriptional programme consisting of
upregulation of pro-survival and metastatic genes, including
FOXA1, GATA5 and Sox2.141 Interestingly, metabolic crosstalk
between ACLY–ACSS2 and the mevalonate pathway has also
been observed in PDA, with acetyl-CoA serving as the predomi-
nant substrate for cholesterol and steroid synthesis.140 The
metabolic products of the mevalonate pathway have well-
characterised roles not only in the post-translational modification
of oncogenes, including the farnesylation of Ras, but also on the
epigenetic landscape through regulation of histone deacetylases
(HDACs) and DNA methyltransferases (DNMTs).142 Importantly,
inhibition of the mevalonate pathway with statins facilitates
widespread effects on microRNA (miRNA) expression, reduced
transcription of genes involved in folate metabolism such as
dihydrofolate reductase (DHFR) as well as attenuation of HDAC
activity leading to CDKN1A promoter acetylation and transcription
of the tumour suppressor p21.142
Overall, the activation of lipogenic enzymes such as FASN, ACLY
and ACSS2 are not just secondary events arising from hyperactive
oncogenic signalling, but rather exist in a complex network
involving reciprocal regulation. Furthermore, many of these
enzymes generate metabolic by-products that exert profound
effects on gene expression and whole-cell physiology, and their
functions must, therefore, be considered in this broad context.
FATTY ACIDS SUPPORT TUMORIGENESIS AND CANCER
PROGRESSION
It is widely appreciated that FAs are essential to cancer cells
because they sustain membrane biosynthesis during rapid
proliferation, and provide an important energy source during
conditions of metabolic stress. However, more intricate oncogenic
roles of FAs and their by-products are beginning to be uncovered.
These predominantly focus on the latter acting as signalling
molecules that can directly regulate cellular homoeostasis, by
modulating the surrounding microenvironment to create condi-
tions that are conducive for tumour progression. The complex
interplay of these multifaceted and diverse biological functions is
discussed below.
Membrane structure and fluidity
FAs are essential building blocks for maintaining the structure and
fluidity of the cell membrane. One of the advantages of the
elevated rate of de novo lipogenesis in cancer cells is the synthesis
of saturated and monounsaturated FAs, which are inherently more
stable than polyunsaturated FAs because they contain fewer
double bonds that can be targeted for peroxidation (Fig. 4a).143
Cancer cells with a higher degree of membrane saturation are less
susceptible to oxidative stress induced by chemotherapeutic
agents such as doxorubicin, whilst combinatorial inhibition of de
novo lipid synthesis, either through siRNA knockdown of lipogenic
enzymes or treatment with soraphen (an ACC inhibitor),
synergistically increases cytotoxicity.143
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Intracellular levels of cholesterol can also dramatically modulate
membrane architecture that impacts cell migration and ultimately
metastatic dissemination. Interestingly, incorporation of choles-
terol in membranes generally reduces fluidity and consequently
inhibits metastasis by limiting the capacity for a cell to change its
shape, a process that is essential during the epithelial-to-
mesenchymal transition (EMT) and intra-/extravasation from blood
vessels (Fig. 4a).144 In support of this, cells undergoing EMT display
increased cholesterol efflux through upregulation of the ATP-
binding cassette transporter ABCA1, whilst human tumours
overexpressing ABCA1 have strikingly higher rates of distant
metastases.144 It is important to note, however, that increasing
membrane rigidity can also be advantageous for cancer cells. This
is particularly relevant for the development of multi-drug-resistant
tumours, which typically contain lower levels of endogenously
synthesised cholesterol and are consequently less permeable to
anticancer agents.145
Epidemiological studies have highlighted controversial roles for
aberrant cholesterol metabolism in cancer, thus raising important
considerations for how tumours actually utilise cholesterol, and
how it may be therapeutically exploited.146 For instance, elevated
serum cholesterol levels are associated with increased incidence
and recurrence of prostate cancer, whilst inhibition of its
biosynthesis by using statins reduces colorectal, breast and
endometrial cancer mortality.147–149 Conversely, numerous studies
have shown either no association between cholesterol and cancer,
or potential carcinogenic effects of statins.150,151 Therefore,
resolving these disparate clinical outcomes remains a significant
challenge and source of uncertainty for pursuing therapies
targeting cholesterol metabolism. Perhaps insights can be gained
from preclinical studies that consistently demonstrate a role for
cholesterol in tumorigenesis, but in specific contexts. As discussed
previously, during metastatic dissemination, cancer cells actively
efflux cholesterol to maintain low membrane concentrations, thus
promoting plasma membrane fluidity and EMT.144 In the case of
advanced-stage disease, low cholesterol levels may, therefore, be
advantageous for metastatic cells and contribute to cancer
progression. On the other hand, the establishment of primary
tumours are highly dependent on pro-proliferative and growth-
stimulatory signalling pathways, and increased membrane cho-
lesterol concentrations promote this through the formation of
lipid rafts.152 Indeed, cholesterol-rich lipid rafts facilitate the
accumulation of receptor tyrosine kinases, such as HER2 and IGF-1,
to rapidly induce oncogenic signalling including PI3K–AKT.153 In
this context, inhibiting cholesterol biosynthesis may be beneficial.
Overall, in order to successfully exploit cholesterol metabolism as
a therapeutic target in cancer, it may be necessary to first consider
how the dependency of cancer cells on cholesterol changes
with disease progression. With this in mind, actively lowering
cholesterol in an advanced disease-stage setting may have limited
or adverse effects as carcinoma cells present in metastases require
low levels for EMT.144 Conversely, blocking cholesterol synthesis
with statins could be more effective at inhibiting cancer initiation

















































Fig. 4 Fatty acids (FAs) regulate membrane architecture and oncogenic signalling pathways. a Membrane fluidity is largely determined by
cholesterol levels and degree of FA desaturation. Cancer cells displaying elevated de novo lipogenesis can synthesise saturated phospholipids,
which not only increases membrane rigidity, but also protects against peroxidation induced by reactive oxygen species. Conversely, highly
migratory cells display more fluid membranes as a result of increased desaturation and cholesterol abundance, thus contributing to the
epithelial-to-mesenchymal transition and metastasis. b FAs and their synthetic products also function as secondary messengers in signalling
pathways, with the best characterised being the phosphoinositides. PI(3,4,5)P3 activates oncogenic AKT, and contributes to hyperactivation of
mTORC1 and mTORC2. In addition, PI(3)P stimulates SGK3 that promotes tumorigenesis independently of AKT. Finally, phosphatidic acid can
also directly bind to and activate the mTOR complexes. Abbreviations: PI3Kα, phosphoinositide 3-kinase α; PI(4,5)P2, phosphatidylinositol (4,5)-
bisphosphate; PI(3,4,5)P3, phosphatidylinositol (3,4,5)-trisphosphate; PI(3,4)P2, phosphatidylinositol (3,4)-bisphosphate; PI(3)P, phosphatidyli-
nositol 3-phosphate; mTORC, mammalian target of rapamycin complex; PA, phosphatidic acid; PTEN, phosphatase and tensin homologue;
SGK3, serum- and glucocorticoid-induced protein kinase-3; INPP4B, inositol polyphosphate-4-phosphatase type II B.
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more dependent on cholesterol for sustaining growth-factor-
induced signalling.153
Pro-tumorigenic signalling molecules
FAs are used for the synthesis of bioactive lipids that support
cellular proliferation and survival by functioning as secondary
messengers in signal transduction pathways. PtdIns are among
the best-characterised signalling lipids, and are composed of two
FA chains connected to an inositol ring and a glycerol backbone.74
The hydroxyl groups of the inositol ring can be phosphorylated at
positions 3, 4 and 5 to generate several phosphoinositide species
including monophosphorylated PI(3)P, PI(4)P and PI(5)P, dipho-
sphorylated PI(3,4)P2, PI(3,5)P2 and PI(4,5)P2 and finally tripho-
sphorylated PI(3–5)P3 (also known as PIP3).
74 Of these, PIP3 is the
most extensively studied because it facilitates the localisation of
AKT to the plasma membrane, leading to its subsequent activation
by phosphoinositide-dependent kinase 1 (PDK1) and mTORC2
downstream of hyperactive PI3K signalling (Fig. 4b). The multi-
faceted roles of AKT in oncogenesis have been alluded to earlier in
this review: from a metabolic viewpoint, AKT stimulates glucose
uptake by stabilising GLUT1/4, and triggers de novo lipogenesis
and anabolic metabolism through mTORC1-dependent and
-independent mechanisms.62,84,89 Moreover, AKT promotes survi-
val by phosphorylating and inhibiting several pro-apoptotic
proteins including BAD, procaspase-9 and the FOXO transcription
factors, which positively regulate the expression of apoptotic
enzymes.154 The regulation of oncogenic signalling by phosphoi-
nositides can also be mediated through the activity of lipid
phosphatases such as PTEN and inositol polyphosphate-4-
phosphatase type II (INPP4B). PTEN in particular has been the
subject of extensive study, as it acts as the main negative
regulator of PI3K signalling by dephosphorylating PIP3 to PIP2.
74
Conversely, other phosphatases involved in phosphoinositide
metabolism can activate PI3K signalling independently of AKT. For
instance, the sequential conversion of PIP3 into PI(3,4)P2 and PI(3)P
by Src homology 2-containing inositol 5-phosphatase (SHIP)
and INPP4B, respectively, activates SGK3 (Fig. 4b).155–157
PI3K–SGK3 signalling initiated by PI(3)P and INPP4B drives cell
proliferation, invasion and tumour growth, demonstrating that
phosphoinositides functioning as secondary messengers can
dynamically regulate the initiation of different signalling axes,
thus providing compensatory pro-tumorigenic effects.155,156
Since PtdIns are the precursors of phosphoinositides, their
spatial and temporal regulation are essential in regulating several
cellular processes. Consequently, features associated with normal
FA metabolism including localisation and transport of PtdIns, as
well as their enzymatic conversion into various phosphoinositide
species, are often exploited by cancer cells to fuel pro-proliferative
signalling. In terms of co-ordinating the spatial localisation of
PtdIns pools – and by extension their downstream conversion into
phosphoinositide secondary messengers – PtdIns transfer proteins
(PITPs) function as central regulators.158 An important feature of
PITPs is their capacity to transfer PtdIns between subcellular
compartments in an ATP-independent fashion, thereby efficiently
localising PtdIns that are initially synthesised in the ER to other
membranes with comparably lower PtdIns concentrations, such as
the plasma membrane.159 A specific subclass of PITPs are type 1
START-like PITPs that encompass three main isoforms: PITPα, PITPβ
and RdgBβ.159 PITPα is arguably the best-characterised isoform,
and most widely associated with disease pathology due to its high
affinity for PtdIns binding.159 For instance, PITPα is required for
normal neuronal development by regulating the co-ordinated
accumulation of PtdIns to the leading edge of axons, thus
ultimately contributing to localised PIP3 generation, by PI3K-
enhanced AKT signalling, and axon elongation.160 An integral role
for PITPα in promoting signal transduction pathways initiated by
RTKs has also been described in the context of EGFR activation,
suggesting that PITPα could also be closely associated with
oncogenic signalling.161 This probably involves the PITPα-
mediated provision of PtdIns to the plasma membrane, leading
to the localised accumulation of a phosphoinositide pool at
activated RTKs and downstream synthesis of mono-, di- and
triphosphorylated phosphoinositide secondary messengers.161
Interestingly, PITPα has also been implicated in tumour metastasis
through an intricate mechanism linking PIP2 and inositol 1,4,5-
triphosphate (IP3) signalling in platelet cells.
162 In this model,
PIPTα drives the formation of a specific pool of PIP2 that is utilised
for IP3 synthesis through enhanced phospholipase Cγ (PLCγ)
activity.162 A major implication of this PIPTα–PIP2–IP3 signalling
axis is the production of thrombin by platelets, allowing them to
adhere to circulating tumour cells and facilitating their dissemina-
tion to distant tissues.162 Overall, these findings illustrate that
dysregulated FA metabolism in the form of aberrant transport and
localisation of lipid molecules, namely PtdIns, has notable effects
on the spatial production of secondary messengers that ultimately
impact on cell-signalling pathways.
In terms of phosphoinositide metabolism, growth-factor stimu-
lation promotes the synthesis of PIP3 within seconds, leading to
the rapid induction of PI3K–AKT signalling. This implies the
existence of a highly co-ordinated enzymatic system that can
efficiently catalyse the conversion of membrane-localised pools of
PtdIns into pro-tumorigenic phosphoinositides. Indeed, the
scaffold protein IQGAP1 is essential in this process, as it can
simultaneously bind PI4KIIIα, PIPKIα and PI3K to facilitate the
sequential synthesis of PI(4)P, PI(4,5)P2 and PI(3,4,5)P3 from PtdIns,
respectively.163 It is well accepted that PIP2 is present in excess of
up to 100-fold when compared with PIP3 at the plasma
membrane, even in stimulated cells.164 Therefore, the spatial
regulation of PIP3 generation mediated by IQGAP1 – which, in
turn, is dependent on the presence of localised pools of PIP2 and
PtdIns at sites of activated RTKs – could represent the rate-limiting
step in the efficient synthesis of this secondary messenger, as
opposed to the general supply of FAs per se.163
In addition to PtdIns, PAs can serve as potent signalling
molecules. The predominant source of PAs is from the hydrolysis
of PC and PE by phospholipase D 1/2 (PLD1/2); however, glycerol-
3-phosphate (G3P) can also be used as a substrate for glycerol-3-
phosphate acyltransferase (GPATs) to synthesise PA.165 Notably,
PAs can directly bind and stabilise mTOR, thus leading to
increased activity of both mTORC1 and mTORC2.166 Inhibition of
PA synthesis reduces mTORC2-dependent phosphorylation of AKT
on Ser473, suggesting that mTOR, in addition to sensing nutrients
including amino acids,167,168 also integrates signals from lipids to
ultimately coordinate cellular growth and proliferation.169 It is
particularly interesting to note that PAs can directly compete with
mTOR inhibitors such as rapamycin for binding to the mTOR
complexes.169 This finding may have important clinical implica-
tions, as it suggests that the levels of PA and the activity of
enzymes involved in its synthesis, such as PLD and GPAT, could
influence sensitivity to mTOR inhibition.169
Bioactive lipids can also stimulate cell proliferation through
autocrine and paracrine mechanisms that require the activation of
G-protein-coupled receptors (GPCRs) (Fig. 5). Among the most
potent of these lipid species are lysophosphatidic acids (LPAs)
consisting of a phosphate head group attached to a glycerol
backbone and a single FA tail.170 The production of LPA is
influenced by the abundance of various lipid species. For instance,
LPA can be generated through two main mechanisms: the first
involves cleavage of existing phospholipids at the sn-2 position by
phospholipases (PLAs) to release a lysophospholipid and a FA, and
the second requires the lysophospholipase D activity of autotaxin
to convert LPC into LPA extracellularly.171 In terms of the first
mechanism in particular, cells must have increased synthesis of PA
that specifically releases LPA following cleavage by phospholi-
pases. In this context, a dominant role for PLD2 has been
described, with gastric, breast and colorectal cancers displaying
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elevated protein expression and activity.172 Moreover, DAG can
directly contribute to the cellular pool of PA through the
enzymatic activity of DAG kinases (DGKs).173 Notably, DGKα has
been shown to promote the synthesis of PA from DAG, which can
subsequently be used to generate LPA in fibrotic tissues, thus
negatively impacting the efficacy of radiation therapy.174 There-
fore, dysregulated lipid metabolism can directly regulate the
generation of LPA by modulating the cellular pool of PA. The latter
is also activated by CDP to form CDP–DAG that can then be
converted into glycerophospholipids PtdIns, PG and cardiolipin.
Importantly, this biosynthetic pathway demonstrates how
changes in LPA and/or PA might play a crucial role in regulating
intracellular signalling and trafficking by affecting the pool of PI,
which acts as the major precursor of all phosphoinositides.
Several LPA species containing FA tails of varying carbon length
and desaturation exist, with the most common and biologically
relevant being LPA(16:0) and LPA(18:1).175 Human cells express six
LPA receptor (LPAR) genes encoding LPAR1–6 to which LPAs bind
and exert their pro-tumorigenic effects.170 These include activa-
tion of PI3K and Ras–MAPK signalling that have well-established
roles in driving cell proliferation by inhibiting negative regulators
of cell-cycle progression such as p21, p27 and p15, as well as
induction of RHO GTPases that promote cell migration through
remodelling of the actin cytoskeleton.176–178 LPAs are also
implicated in autocrine and paracrine-signalling networks, thus
serving as important intermediaries between tumour cells and the
microenvironment. Indeed, in pancreatic ductal adenocarcinomas
(PDAC), pancreatic stellate cells (PSCs) and cancer-associated
fibroblasts (CAFs) display elevated synthesis of LPCs from glucose
and glutamine, and ultimately release these lysophospholipids
into the surrounding microenvironment.179 PDAC cells display
increased secreted levels of autotaxin, facilitating the rapid and
localised conversion of LPC into LPA, and consequent activation of
AKT signalling through stimulation of LPAR1/2.179 Pharmacological
inhibition of autotaxin significantly reduces PDAC tumour growth
in vivo, and this effect is more pronounced following co-
transplantation with PSCs, thus highlighting the importance of
the latter in dynamic lipid remodelling through local LPC release
and autotaxin-mediated conversion into LPA.179 These results also
suggest that therapeutically targeting metabolic interdependen-
cies between the primary tumour and the surrounding micro-
environment could be an effective strategy for the treatment of
PDAC.179
Eicosanoids remodel the tumour microenvironment
An important subclass of bioactive lipid molecules are eicosanoids.
The omega-6 FA arachidonic acid (AA) serves as the main
precursor of several eicosanoid species, including prostaglandins,
thromboxanes and leukotrienes, each of which has pro-
inflammatory and pro-tumorigenic effects.72 There are three main
mechanisms through which cancer cells can obtain AA: (1) direct
exogenous uptake by using specific transporters, such as CD36
and TWIK-related AA-stimulated K+ (TRAAK) channels, (2) de novo
synthesis from linoleic acid (LA) and (3) cleavage of the sn-2
position of existing membrane phospholipids through the
enzymatic activity of phospholipases. Each of these processes
has been extensively reviewed previously.72,180 The predominant
enzymes involved in prostaglandin production are the prosta-
glandin G/H synthetases COX1 (PTGS1) and COX2 (PTGS2). The
former is constitutively active and regulates normal cellular
processes including angiogenesis and blood clotting, whilst
COX2 expression is selectively induced by growth factors and
chemokines, and is, therefore, more closely linked with inflamma-
tion.72 The cyclo-oxygenase and peroxidase activities of COX
enzymes sequentially convert AA into prostaglandin G2 (PGG2)
and prostaglandin H2 (PGH2), respectively.72 Other eicosanoids
including PGE2, PGD2, prostacyclins and thromboxanes can be
derived from PGH2.72
Prostaglandins exert pro-inflammatory and pro-tumorigenic
effects in both autocrine and paracrine fashions by activating
G-protein-coupled prostanoid receptors including EP1–4, DP1,
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Fig. 5 Remodelling of the tumour microenvironment by bioactive lipids. Eicosanoids and lysophosphatidic acid species can be secreted into
the surrounding microenvironment and stimulate cell proliferation through both autocrine and paracrine mechanisms. Arachidonic acid (AA)
serves as the main precursor for eicosanoid synthesis, and these include pro-inflammatory prostaglandins, leukotrienes and eicosatetraenoic
acids. PGE2 can stimulate cell proliferation through autocrine and paracrine signalling, and this is largely mediated through the activation of
EP1–EP4 receptors. Moreover, prostaglandins contribute to immunosuppression by attenuating the activation of natural killer, dendritic and
cytotoxic T cells. Lysophosphatidic acids are also relevant signalling molecules, and can be produced intracellularly from glycerol-3-phosphate
or phosphatidic acid, or extracellularly through the enzyme autotaxin, which uses existing phospholipids, such as phosphatidylglycerols and
phosphatidylethanolamines as substrates. Similar to eicosanoids, lysophosphatidic acids exert their tumorigenic effects by binding to the
LPAR family of G-protein-coupled receptors. Abbreviations: RTK, receptor tyrosine kinase; LOX, lipoxygenase; COX, cyclo-oxygenase; PGG2,
prostaglandin G2; PGH2, prostaglandin H2; PGE2, prostaglandin E2; PGI2, prostaglandin I2; TXA2, thromboxane A2; HETE, hydroxytetraenoic
acid; EP, prostaglandin E2 receptor; NK, natural killer cell; G3P, glyceraldehyde 3-phosphate; GPAT, glycerol-3-phosphate acyltransferase; PA,
phosphatidic acid; PLA2, phospholipase A2; LPA, lysophosphatidic acid; LPAR, lysophosphatidic acid receptor; ATX, autotaxin.
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Tumour-initiating events triggered by prostaglandins include
PGE2-mediated activation of PI3K signalling and induction of
ERK following binding to the EP4 receptor, thus stimulating
proliferation, as well as cell migration through stabilisation of β-
catenin and c-MET induction.182,183 In addition, in models of
colorectal cancer, intracellular PGE2 can induce phosphorylation
and activation of EGFR, leading to induction of MMPs and a
consequent promotion of cell invasiveness.184 Prostaglandins can
also promote adaptation to microenvironmental stress conditions
such as hypoxia.185 Under hypoxic conditions, HIF1α induces the
expression of COX2, leading to a concomitant overproduction
of PGE2 that stimulates tumour angiogenesis in a VEGF- and
chemokine (c–X–c motif) ligand 1 (CXCL1)-dependent
manner.186,187 It is interesting to note that at least in colorectal
cancer, HIF1 can actually induce cell-cycle arrest by binding to β-
catenin and displacing transcription factor 4 (TCF4), thereby
blocking the formation of a functional β-catenin–TCF4 transcrip-
tional complex and inhibiting the transcription of genes involved
in proliferation.185,188 This mechanism is particularly intricate
because it demonstrates how the crosstalk between HIF and
prostaglandin signalling can induce a ‘hibernation’ state in cancer
cells that is characterised by sustained nutrient acquisition
through vascularisation, and reduced energy expenditure.185,188
The main implications of this could be that cancer cells are better
equipped to recover from hypoxia and resume proliferation
immediately following reoxygenation.
Further to the direct effects on tumour cells, prostaglandins can
also modulate the surrounding microenvironment, and this has
been extensively demonstrated in the context of inhibition of the
anti-tumour immune response (Fig. 5). One mechanism through
which elevated PGE2 promotes tumour immune evasion is by
abrogating co-stimulation and complete activation of CD8+ T
lymphocytes mediated by binding of intercellular adhesion
molecule 1 (ICAM-1) expressed on tumour cells and the lymphocyte
receptor LFA-1.189 In addition, accumulation of conventional type 1
dendritic cells (cDC1s) is essential for initiating the anti-tumour
immune response, and requires the infiltration of natural killer cells
within the tumour microenvironment.190 However, in models of
BRAFV600E mutant melanomas, overproduction of COX2-derived
PGE2 directly inhibits the production of CXCL1 and chemokine (c–C
motif ligand 5 (CCL5) chemokines by natural killer (NK)) cells,
thereby attenuating the migration of cDC1s to the tumour site.190
Importantly, the accumulation of NK and cDC1 cells is associated
with better prognosis in melanoma and breast cancers, indicating
that the immunomodulatory properties of prostaglandins could
have significant clinical implications.190 Indeed, the response of
melanomas harbouring BRAFV600E mutation to anti-programmed
cell death protein 1 (PD1) immune checkpoint inhibitors is
significantly improved following combinatorial therapy with COX
inhibitors including aspirin and celecoxib.191
An additional pathway for AA metabolism is its conversion into
arachidonyl-CoA following the ligation of acetyl-CoA catalysed by
the acyl-CoA synthetase ACSL4.192 Arachidonyl-CoA can be
subsequently esterified to form TAGs and incorporated into
phospholipids, or utilised as a substrate by COX2 to enhance
eicosanoid biosynthesis.193 ACSL4 is also implicated in the
localised release of AA in the mitochondria, and this requires
the transport of arachidonyl-CoA to the inner mitochondrial
membrane via the translocator protein (TSPO) and hydrolysis by
acyl-CoA thioesterase 2 (ACOT2).192 Importantly, several studies
have implicated ACSL4 in tumorigenesis, with advanced-stage
breast, colorectal, hepatocellular and prostate carcinomas display-
ing increased expression at both the mRNA and protein levels.192
The oncogenic effects of elevated ACSL4 are twofold. Firstly,
mitochondrial AA that accumulates as a consequence of ACSL4
activity is predominantly directed towards the biosynthesis of
leukotrienes including 5-, 12- and 15-hydroxyeicosatetraenoic acid
(HETE).194 These metabolites potently activate leukotriene B4
receptors and potentiate several oncogenic signalling pathways
including PI3K–AKT and Wnt–β-catenin, thus promoting cell
migration and proliferation in breast and prostate cancer cells.194
Secondly, the excessive accumulation of unesterified polyunsatu-
rated FAs (PUFAs) promotes apoptosis through induction of the
ER-stress response, activation of caspase-3 and tumour necrosis
factor α (TNFα) signalling.195 ACSL4 limits the cytotoxicity
associated with elevated cellular pools of unesterified AA by
producing arachidonyl-CoA, thereby increasing the apoptotic
threshold and survival of castration-resistant prostate cancer
(CRPC) cells.192 It is important to note, however, that the localised
accumulation of arachidonyl-CoA and AA in the mitochondria can
also contribute to membrane depolarisation and electron trans-
port chain uncoupling, leading to increased ROS production.196 If
left unchecked, the elevation in ROS levels can increase lipid
peroxidation and cell death induced by ferroptosis.196 Thus,
cancer cells must also have adequate anti-oxidative responses,
including increased Nrf2 activity and NADPH/glutathione bio-
synthesis, to capitalise on the pro-tumorigenic effects of ACSL4
overexpression.
THERAPEUTICALLY EXPLOITING FATTY ACID METABOLISM IN
CANCER
Given the extensive role of FAs in cancer pathogenesis, there is
substantial clinical interest in developing therapies that target FA
metabolic reprogramming. The majority of inhibitors designed for
this purpose target specific enzymes involved in de novo FA
synthesis and exogenous lipid uptake (Table 1); however, there is
also a resurgent interest in understanding how specific dietary
interventions may synergistically improve the efficacy of existing
cancer therapeutics. Current strategies and considerations for
successfully targeting the tumour lipidome are discussed below.
Targeting FASN: a challenging past but promising future
In terms of therapeutically targeting dysregulated lipid metabo-
lism in cancer, FASN has arguably received the most widespread
interest, and this is not surprising given its multifaceted roles in
supporting both anabolic metabolism and oncogenic signalling.
However, the transition of FASN inhibitors from bench to bedside
has largely been elusive, and marked with several challenges and
shortcomings. This is particularly relevant for the first-generation
FASN-targeting drugs, such as C75, orlistat and cerulenin. These
compounds initially showed great promise in preclinical studies,
with both significantly reducing tumour xenograft growth and
inducing cell-cycle arrest, whilst also sensitising breast cancer cells
to ROS-inducing chemotherapies by decreasing the synthesis of
saturated lipids.102,197,198 In spite of these successful outcomes in
the laboratory, significant clinical obstacles included detrimental
systemic side effects characterised by drastic weight loss and
anorexia,199 thus highlighting the involvement of FA metabolic
enzymes in both disease pathology and normal whole-body
metabolic homoeostasis. Indeed, recent studies have demon-
strated that in both normal and malignant ovarian models, FASN
expression largely reflects the proliferative and growth state of a
cell, rather than malignancy per se.200 Interestingly, proliferative
non-malignant ovarian surface epithelial (OSE) and fallopian tube
secretory epithelial (FT) cells express levels of FASN comparable
with ovarian cancer cell lines, and display similar sensitivities to
FASN inhibition by C75 and G28UCM.200 These observations,
however, do need to be reconciled with the commonly held
notion that elevated de novo lipogenesis driven by FASN is a
metabolic hallmark of cancer, but not normal cells, and therefore,
the latter should be largely insensitive to FASN inhibition. Previous
studies demonstrating that FASN-catalysed endogenous FA
synthesis in normal liver and adipose tissue is actually stimulated
by a high-carbohydrate diet not only add another layer of
complexity to this notion, but also suggest that monitoring
Reprogramming of fatty acid metabolism in cancer
N Koundouros and G Poulogiannis
15
nutrient availability may be indispensable in determining the
whole-body sensitivity of noncancerous cells to FASN inhibi-
tion.201 Thus, in terms of clinical implications, it will be important
to characterise FASN as a potential general proliferative
marker – rather than being solely associated with malignancy – as
well as understanding the effects of nutrition on the dependence
of normal tissues for FASN-driven lipogenesis.
More recently, next-generation FASN inhibitors, including TVB-
3166 and TVB-2640, have shown tremendous anti-tumour potential
in preclinical breast and colorectal cancer models, as well as
excellent tolerability and limited systemic toxicity in early-phase
clinical trials.202,203 One explanation for the improved tolerance of
the next-generation inhibitors could be that in contrast to C75 and
cerulenin, TVB-3166 and TVB-2640 do not contribute to the indirect
activation of CPT1 in peripheral tissue.202 The induction of β-
oxidation peripherally following C75 or cerulenin treatment
contributes to increased energy expenditure, loss of adipose tissue
and significant weight loss, whereas next-generation inhibitors
display higher specificity for FASN with limited off-target
effects.202,204 Accompanying the development of novel FASN
therapies is a concerted effort to better stratify patients who will
actually benefit from FASN inhibition. A potential strategy for this
endeavour may include assessment of HER2 status, particularly in
light of the connections between FASN expression and signalling
downstream of HER2, which have been discussed earlier in this
review.82 Indeed, there are now two clinical trials in Phase 2 stages
evaluating the combinatorial effects of TVB-2640 and chemother-
apy in HER2-positive breast cancer (Clinical Trial ID: NCT03179904)
and astrocytomas (Clinical Trial ID: NCT03032484).205
Targeting ACLY and ACSS2: limiting the metabolic substrates for
lipogenesis
Increased expression and activity of ACLY is observed across
several tumour types including glioblastoma, colorectal, breast
and hepatocellular carcinomas.34 Considering its role in
generating acetyl-CoA, which is the main substrate for lipogenesis
and cholesterol synthesis, targeting ACLY has proven to be an
effective therapy for treating hypercholesterolaemia and hyperli-
pidaemia.206 Importantly, several ACLY inhibitors including ETC-
1002 (Phase 2/3 clinical trials) and hydroxycitrate (randomised
control trials) have shown high efficacy in lowering low-density
lipoprotein–cholesterol and good tolerability in patients with
cardiovascular disease and type 2 diabetes (Table 1), thus
indicating that ACLY inhibition could represent a well-tolerated
therapeutic strategy.207–211
There is considerable interest in ACLY as a target for anticancer
drugs; however, clinical trial studies in this context are far more
limited when compared with dyslipidaemia cases. Nevertheless,
there is a plethora of preclinical evidence to support the integral
role of ACLY in tumorigenesis and the potential clinical benefits
for its selective inhibition. In particular, both genetic and
pharmacological targeting of ACLY significantly reduces the
growth of lung and prostate tumour xenografts, and this anti-
tumorigenic effect is more pronounced in highly glycolytic cells.34
Perhaps this is not surprising given that ACLY largely generates
acetyl-CoA from glucose-derived citrate, but it does suggest that
metabolic stratification of tumours may improve the potency of
ACLY inhibitors such as SB-204990 and hydroxycitrate.34 This is
particularly relevant when one considers the current limitations of
ACLY-targeted cancer therapeutics, which predominantly include
the relatively high drug concentrations required for complete
inhibition of ACLY activity. Thus, by identifying tumours with high
rates of glucose consumption that are consequently more
dependent on ACLY activity for glycolysis-fuelled lipogenesis,
dosing regimes with lower drug concentrations could be
implemented.34 Furthermore, structural studies focussing on
characterising the protein domains of the ACLY tetramer have
revealed novel hydrophobic regions near the citrate-binding site
that have untapped potential for improving the drugability of
ACLY.212
Table 1. Non-exhaustive list of therapies targeting lipid metabolism as cited in the main text.
Target Drug Drug development stage Disease type
FASN C75 Preclinical Breast cancer197,198
Cerulenin Preclinical Breast cancer197,198
Orlistat Preclinical Breast cancer198
FDA-approved (marketed as Alli
and Xenical)
Obesity management
TVB-3166 Preclinical Colorectal, breast cancer202,203
TVB-2640 Phase 2 clinical trials Breast cancer (ID: NCT03032484, NCT03179904
and NCT02223247)205
ACLY SB-204990 Preclinical Lung, prostate cancer34
Hydroxycitrate Randomised controlled trial Hypercholesterolaemia and obesity210,211
ETC-100 (dual ACLY inhibitor/AMPK
activator)





SCD SSI-4 Preclinical Hepatocellular carcinoma219
Betulinic acid Preclinical Colorectal cancer220
MF-438 Preclinical Lung cancer221
Whole-body
metabolism
Omega-3 FA supplementation Double-blind randomised
control trial
Rheumatoid arthritis227
Omega-3 FA supplementation Phase 1 clinical trial Breast cancer (ID: NCT0182580)
Omega-6:omega-3 FA ratios of 46:1,
10:1 and 1.3:1
Preclinical Prostate cancer224
FASN fatty acid synthase, ACLY ATP–citrate lyase, ACSS2 acetyl-CoA synthetase 2, SCD stearoyl-CoA desaturase
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Another approach for implementing ACLY inhibition as a
therapeutic strategy for cancer is to consider its role in signalling
networks that regulate cellular responses to energy stress. For
instance, in CRPC cells, inhibition of ACLY disrupts ER and energy
homoeostasis in CRPC cells, leading to AMPK activation and
sensitisation to androgen receptor inhibitors.213 Intriguingly,
supplementation of exogenous FAs is sufficient to restore
hormone resistance in CRPC cells by alleviating the ER and energy
stress instigated by ACLY inhibition, demonstrating the impor-
tance of an ACLY–AMPK network in regulating energy homo-
eostasis that could be exploited pharmacologically.213 Indeed,
several AMPK-activating therapies such as metformin have shown
anticancer and anti-inflammatory properties, and importantly are
well tolerated in patients.214 Notably, some ACLY inhibitors
currently used for the treatment of hypercholesterolaemia, such
as ETC-1002, are also dual activators of AMPK, and although not
yet investigated, it would be interesting to assess the applicability
of these drugs in the cancer therapy context.207 While dual
targeting of ACLY and AMPK does seem like an attractive
therapeutic strategy, it is necessary to acknowledge the instances
in which the latter may actually promote tumorigenesis. For
instance, the presence of functional LKB1 is essential for complete
AMPK activation, and given that this kinase is frequently
mutated – including in 34% of lung carcinomas and 20% of
cervical cancers – it may be necessary to first stratify patients
based on LKB1 status to evaluate the true therapeutic potential of
AMPK activators.215 Furthermore, the extent of mTORC1 hyper-
activation should also be considered, as tumours that are
dependent on mTOR signalling are more likely to have a better
response to AMPK activation.214 Closely linked with this idea are
the regulatory feedback mechanisms that exist between mTORC1
and mTORC2–AMPK is a well-characterised negative regulator of
mTORC1; however, the potential compensatory effects leading to
mTORC2 hyperactivation and initiation of pro-tumorigenic signal-
ling, such as induction of AKT, must be carefully considered.214
Finally, AMPK activation promotes calcium-induced migration of
prostate cancer cells through calmodulin-dependent protein
kinase (CaMKKB) signalling.216 Thus, it appears that therapeutically
exploiting ACLY and AMPK activities requires extensive molecular
characterisation of a patient’s tumour, and may be context-
dependent.
Although the effects of ACLY inhibition predominantly focus on
FA synthesis, an additional biological feature of reducing acetyl-
CoA synthesis is remodelling histone acetylation and gene
expression patterns.135 Given the essentiality of acetyl-CoA in
other metabolic pathways and gene regulation, it may be
necessary to undertake parallel transcriptomic and metabolomic
profiling of adjacent normal tissue in order to fully ascertain the
systemic consequences of inhibiting acetyl-CoA production. To
improve the selective modulation of acetyl-CoA production in
tumour cells, whilst simultaneously sparing healthy tissue, an
alternative strategy could be to exploit therapeutic windows
arising from the plasticity of cancer cells in metabolically
challenging microenvironments. With regard to acetyl-CoA
metabolism, tumours specifically upregulate ACSS2 under condi-
tions of hypoxia or lipid deprivation, leading to increased acetate
uptake and ligation with CoA to produce acetyl-CoA for de novo
lipogenesis.33 Importantly, a HIF–SREBF2 signalling axis drives
ACSS2 expression and confers exquisite sensitivity to its inhibition
in hypoxic or otherwise metabolically stressed tumours.33
Although the development of ACSS2-specific inhibitors is lagging
considerably behind ACLY-targeted therapies, efforts are being
made to bridge this gap through identification of novel selective
inhibitors by using high-throughput screens.217 In fact, one of
the most potent compounds identified, N-(2,3-di-2-thienyl-6-
quinoxalinyl)-N'-(2-methoxyethyl)urea, has already been shown
to sensitise chemotherapy-resistant bladder cancers that are
dependent on acetate metabolism to cisplatin.217,218
Targeting SCD: inhibiting fatty acid desaturation
Desaturation of FAs by SCD enzymes produces monounsaturated
FAs that contribute to the synthesis of additional lipid species
including glycerophospholipids and sphingolipids.56 Ectopic SCD
expression promotes EMT and is associated with poor prognosis in
breast and colorectal cancer.56 This provides a therapeutic
opportunity for tumours that depend on canonical SCD-
mediated desaturation, and the effect is more apparent in the
absence of exogenous lipids.55 SCD inhibitors, such as SSI-4,
betulinic acid (BetA) and MF-438, have been shown to induce
apoptosis in cancer cells through multiple mechanisms including
induction of the ER-stress response, modulating mitochondrial
dynamics by altering cardiolipin structure, and growth inhibition
of cancer stem cells (Table 1).55,56,219–221 Interestingly, not all
cancers display sensitivity to SCD inhibition, as they rely on a
compensatory desaturation pathway by utilising FADS2 to
generate sapienate from palmitate.57 In this context, sapienate,
instead of palmitoleate generated from SCD, contributes sub-
stantially to membrane synthesis in hepatocellular and lung
carcinomas.57 As a result, a significant reduction in tumour area is
only observed following combinatorial treatment of hepatocellular
carcinoma xenografts with SCD and FADS2 inhibitors, thereby
blocking any compensatory pathways for obtaining desaturated
FAs.57 In light of these findings, it is important to consider that the
canonical function of FADS2 is the desaturation of LA to γ-linolenic
acid (C18:3n6).180 Given that FADS2 is obligatory for the de novo
synthesis of long-chain omega-6 FAs including AA, it would be
interesting to further investigate the potential regulatory mechan-
isms and microenvironmental conditions that determine the
substrate preference of FADS2. This could yield significant insight
into the interplay of sapienate metabolism with other FA
biosynthetic pathways, and in turn uncover additional compensa-
tory mechanisms that can be exploited therapeutically.
Dietary interventions and cancer therapeutics
Finally, there has been a resurgent interest in studying the role of
dietary interventions in cancer therapy.76,222,223 For instance, it has
been demonstrated that a low-carbohydrate ketogenic diet
dramatically increases the efficiency of PI3K inhibitors and synergis-
tically reduces the growth of PIK3CA-mutant tumours.76 Since
humans can only obtain essential omega-3 and omega-6 FAs from
the diet, it is tempting to speculate that dietary modifications based
on lipid consumption could also have an impact on tumorigenesis.
Omega-3 FAs, including eicosapentaenoic and docosahexaenoic
acids (EPA and DHA, respectively), are widely accepted to have anti-
inflammatory properties by competing with AA for COX2 binding,
and subsequently producing PGE3 instead of PGE2.224 In contrast,
omega-6 FAs, such as LA and AA, are the precursors for pro-
inflammatory eicosanoids.225 The recommended dietary ratio of
omega-6:3 FAs is 1:1; however, the Western diet, which is
significantly enriched in omega-6s, has a ratio of 15:1,225 and this
has significant implications for the progression of several cancers
including breast and colorectal.226 Conversely, a diet rich in omega-3
FAs has been associated with the pathological improvement of
several inflammatory diseases, such as arthritis and asthma224,227,228
(Table 1), as well as reduced risks of developing breast, colorectal
and prostate cancers.224,229 It is important to note, however, that
excessive omega-3 consumption can also have undesirable side
effects including immunosuppression.230 Therefore, it is essential
that careful optimisation of omega-3:omega-6 ratios is undertaken
for each patient. By taking these factors into account, modulation of
dietary fat intake either alone or in combination with existing
therapies could have tremendous potential in therapy response.
CONCLUSIONS AND FUTURE PERSPECTIVES
It is now widely appreciated that cancer cells display significant
rewiring in their FA metabolism. This is not surprising when one
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considers the intricate regulation of lipid homoeostasis in the
context of oncogenic signalling pathways, such as
PI3K–AKT–mTOR and their diverse cellular functions. These are
not just limited to cell intrinsic processes, such as membrane
synthesis or serving as intracellular secondary messengers, but
also extend to remodelling of the entire tumour microenviron-
ment through paracrine-signalling mechanisms. In terms of
therapeutic strategies, it is unlikely that inhibiting single enzymes
or pathways will be sufficient to harness the full potential of
targeting FA metabolism in cancer treatment. Instead, it is
necessary to consider the complex framework within which FAs
and their by-products are synthesised and exert their functions,
including the activation of various compensatory pathways that
sustain FA metabolism, and dynamic interactions with the tumour
microenvironment and nutrient availability. This area of research
holds great promise for the implementation of novel combinator-
ial strategies that exploit the unique dependency of cancer cells
on FAs, both through pharmacological inhibition of metabolic
targets and dietary interventions.
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